Progressive preclinical interstitial lung disease in rheumatoid arthritis
Progressive preclinical interstitial lung disease in rheumatoid arthritis
复制标题
DOI：
10.1001/archinternmed.2007.59
复制
发表时间：
2008-01-28
影响因子：
--
通讯作者：
Rosas, Ivan O.
中科院分区：
文献类型：
--
作者：
Gochuico, Bernadette R.;Avila, Nilo A.;Rosas, Ivan O.
背景资料：早期发现和治疗类风湿关节炎（RA）患者的间质性肺病（ILD）可能会改善疾病进展。本研究的目的是确定无症状的肺部疾病和潜在的治疗目标的患者有RA和临床前ILD（RA-ILD）。方法：64例成人RA和10例成人RA和肺纤维化（RAPF）被称为美国国立卫生研究院，贝塞斯达，马里兰州，并进行高分辨率计算机断层扫描（HRCT）和肺生理学测试。能够调节纤维化的蛋白质定量肺泡fluid.Results：21 64例（33%）RA无呼吸困难或咳嗽有临床前ILD HRCT确定。与无肺部疾病的患者相比，RA-ILD患者的吸烟史显著延长（P
Background: Early detection and treatment for interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) may ameliorate disease progression. The objective of this study was to identify asymptomatic lung disease and potential therapeutic targets in patients having RA and preclinical ILD (RA-ILD).Methods: Sixty-four adults with RA and 10 adults with RA and pulmonary fibrosis (RAPF) were referred to the National Institutes of Health, Bethesda, Maryland, and underwent high-resolution computed tomography (HRCT) and pulmonary physiology testing. Proteins capable of modulating fibrosis were quantified in alveolar fluid.Results: Twenty-one of 64 patients (33%) having RA without dyspnea or cough had preclinical ILD identified by HRCT. Compared with patients without lung disease, patients with RA-ILD had statistically significantly longer histories of cigarette smoking (P